|
562 Companies |
|
307 Products |
|
307 Products |
|
152 Mechanisms of Action |
|
1644 Trials |
|
87579 News |
|
| «12...345678910111213...11141115» |
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku, Onureg (azacitidine oral) / BMS
New trial: ORAZ-351: Oral Azacitidine Maintenance Post-CPX 351 (clinicaltrials.gov) - Apr 4, 2024
P=N/A, N=100, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion date, Trial primary completion date: CLAG-GO for Patients With Persistent, Relapsed or Refractory AML (clinicaltrials.gov) - Apr 4, 2024
P2, N=39, Recruiting, Sponsor: University of Maryland, Baltimore
Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Jan 2024 --> Jun 2026
- | vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer (clinicaltrials.gov) - Apr 4, 2024
P1, N=12, Suspended, Sponsor: Jennifer Eva Selfridge
Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Jan 2024 --> Jun 2026 Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion date, Trial primary completion date: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (clinicaltrials.gov) - Apr 4, 2024
P2, N=31, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2025 Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion date, Combination therapy: SWOG-S1117: Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Apr 4, 2024
P2, N=282, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion date: SWOG-S0703: Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 4, 2024
P2, N=133, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | cyclophosphamide / Generic mfg., etoposide IV / Generic mfg.
Trial completion date, Combination therapy: Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=51, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023 Trial completion date: Dec 2023 --> Dec 2024
- | Trial completion date, Metastases: Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (clinicaltrials.gov) - Apr 4, 2024
P2, N=260, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2023 --> Dec 2024
- | busulfan / Generic mfg.
Trial completion date: Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R (clinicaltrials.gov) - Apr 4, 2024
P2, N=60, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2023 --> Dec 2024
- | veliparib (ABT-888) / AbbVie
Enrollment change, Trial completion date, Metastases: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Apr 4, 2024
P2, N=25, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 N=60 --> 25 | Trial completion date: Jun 2023 --> Dec 2024
- | sorafenib / Generic mfg.
Phase classification: Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 4, 2024
P1, N=51, Completed, Sponsor: National Cancer Institute (NCI)
N=60 --> 25 | Trial completion date: Jun 2023 --> Dec 2024 Phase classification: P=N/A --> P1
- | Journal: Redefining hyperviscosity in acute leukemia: Potential implications for red cell transfusions in the microvasculature. (Pubmed Central) - Apr 4, 2024
In vitro leukostasis in acute myeloid leukemia was primarily driven by WBC with little interaction with Hct/Hgb. This sets the stage for prospective clinical studies assessing how red cell transfusion may affect leukostasis risk in immunophenotypically different acute leukemia patients.
- || Venclexta (venetoclax) / Roche, AbbVie, pevonedistat (MLN4924) / Takeda
P1 data, Journal, IO biomarker: A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. (Pubmed Central) - Apr 4, 2024
P1
The combination of azacitidine, venetoclax and pevonedistat is safe and shows encouraging preliminary activity in patients with relapsed/refractory AML. (NCT04172844).
- | Journal: Co-Occurrence of Pityriasis Amiantacea and Cutis Verticis Gyrata Secondary to Leukaemia Cutis of the Scalp. (Pubmed Central) - Apr 4, 2024
It can lead to secondary verticis gyrata. The co-occurrence of PA and cutis verticis gyrata is rare and previously unreported, highlighting the need for increased awareness among clinicians.
- | Retrospective data, Journal: Secondary hematological malignancies in patients with sarcoma: A single?center retrospective study. (Pubmed Central) - Apr 4, 2024
The incidence of SHMs in sarcoma in the present study was consistent with that reported previously. The presence of SHMs was associated with a poor patient prognosis, especially if treatment for SHMs was not administered.
- | Journal: EXPRESS: GDF11 Level and Its Effect on Prognosis in Patients with Acute Myeloid Leukemia. (Pubmed Central) - Apr 4, 2024
As a conclusion increased serum GDF11 levels in AML patients may be linked to the regeneration ability of leukemic stem cells. There is a need for studies investigating GDF11 expression in myeloblasts.
- || Venclexta (venetoclax) / Roche, AbbVie
Review, Journal: Venetoclax combined with decitabine induced tumor lysis syndrome in a young patient with acute myeloid leukemia: a case report and literature review. (Pubmed Central) - Apr 4, 2024
Based on the experience of this case and related studies, we recommend the prevention of TLS should not be limited to elderly patients taking venetoclax, and it is equally important in young patients. And reduce the dosage of venetoclax when using azole antifungal drugs.
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment open: Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (clinicaltrials.gov) - Apr 3, 2024
P2, N=54, Recruiting, Sponsor: Fred Hutchinson Cancer Center
And reduce the dosage of venetoclax when using azole antifungal drugs. Not yet recruiting --> Recruiting
- | Journal: Extensive Hepatic Infarction due to Polycythemia Vera. (Pubmed Central) - Apr 3, 2024
Splanchnic vein thrombosis is a rare manifestation of venous thromboembolism involving one or more abdominal vessels and is strongly associated with PV. We herein report a case in which hepatic infarction due to PV was saved by conservative treatment.
- | Journal: Tripartite prehabilitation of patients with acute myeloid leukaemia and high-risk myelodysplastic syndromes during intensive chemotherapy before allogeneic haematopoietic stem cell transplantation (COHABILIT): protocol for an innovating prospective multicentre study. (Pubmed Central) - Apr 3, 2024
P=N/A
The results of this protocol will be published in a scientific paper and communicated to the medical staff of the medical centre. NCT03595787.
- | Journal: Lactate utilization enables metabolic escape to confer resistance to BET inhibition in acute myeloid leukemia. (Pubmed Central) - Apr 3, 2024
Low-dose combinations of BETi and oxamate, a lactate dehydrogenase inhibitor, reduced in vivo expansion of BETi-resistant AML in cell line and patient-derived murine models. These results elucidate how AML myeloblasts metabolically adapt to BETi by consuming lactate and demonstrate that combining BETi with inhibitors of lactate utilization may be useful in AML treatment.
- | Journal: The imipridone ONC213 targets ?-ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia. (Pubmed Central) - Apr 3, 2024
Importantly, a patient-derived xenograft from a relapsed AML patient was sensitivity to ONC213 in vivo. Collectively these findings support further development of ONC213 for treating AML.
- | Tibsovo (ivosidenib) / Servier
FDA event, Journal, Combination therapy: FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. (Pubmed Central) - Apr 3, 2024
Furthermore, the rate and duration of complete remission (CR) were improved with ivosidenib versus placebo (CR 47% versus 15%, 2-sided p<0.0001; median duration of CR not estimable [NE] [95% CI 13.0, NE] months versus 11.2 [95% CI 3.2, NE] months). The safety profile of ivosidenib in combination with azacitidine was consistent with that of ivosidenib monotherapy, with important adverse reactions including differentiation syndrome (15%) and QT interval prolongation (20%).
- | Onureg (azacitidine oral) / BMS
Journal, IO biomarker: Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase. (Pubmed Central) - Apr 3, 2024
Oral azacitidine (oral-Aza) treatment results in longer median overall survival (OS) (24.7 vs. 14.8 months in placebo) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy...Inhibition of MPO activity either by using an MPO specific inhibitor or blocking oxidative stress, a known mechanism of MPO, partly reverses the differentiation of LSCs. Overall, our pre-clinical work reveals novel mechanistic insights into oral-Aza and its ability to target leukemic stem cells.
- | Journal: A key to engineering natural killer cells to attack acute myeloid leukemia. (Pubmed Central) - Apr 3, 2024
Overall, our pre-clinical work reveals novel mechanistic insights into oral-Aza and its ability to target leukemic stem cells. Not available.
- | azacitidine / Generic mfg., pioglitazone / Generic mfg.
Journal: Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ? 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase. (Pubmed Central) - Apr 3, 2024
Not available. Not available.
- | Duoenda (mitoxantrone liposomal) / CSPC Pharma
New P3 trial: MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 3, 2024
P3, N=154, Recruiting, Sponsor: Zhongnan Hospital
- | revumenib (SNDX-5613) / Syndax Pharma, Xospata (gilteritinib) / Astellas
Enrollment open: SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation (clinicaltrials.gov) - Apr 2, 2024
P1, N=30, Recruiting, Sponsor: Uma Borate
Not available. Not yet recruiting --> Recruiting
- | azacitidine / Generic mfg.
Journal: Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm? (Pubmed Central) - Apr 2, 2024
comprehensively characterized the epigenomic profile in patients with MDS treated with azacitidine and described a methylation signature-based prognostic tool in predicting responses to azacitidine...Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19392.
- | Idhifa (enasidenib) / BMS, Servier
Journal: Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. (Pubmed Central) - Apr 2, 2024
The parameters for omeprazole increased by 1.86 (90% CI: 1.33, 2.60) and 1.47 (0.93, 2.31)-fold, respectively, compared to omeprazole alone, while those for pioglitazone decreased to 0.80 (90% CI: 0.62, 1.03) and 0.87 (90% CI: 0.65, 1.16)-fold, respectively, in comparison to pioglitazone alone. These findings provide valuable insights into dose recommendations concerning drugs acting as substrates of CYP2D6, CYP2C9, CYP3A4, CYP2C19, and CYP2C8 when administered concurrently with enasidenib.
- || Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment closed, Combination therapy: Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 2, 2024
P1/2, N=188, Active, not recruiting, Sponsor: Astex Pharmaceuticals, Inc.
These findings provide valuable insights into dose recommendations concerning drugs acting as substrates of CYP2D6, CYP2C9, CYP3A4, CYP2C19, and CYP2C8 when administered concurrently with enasidenib. Recruiting --> Active, not recruiting
- || anzurstobart (BMS-986351) / BMS
Enrollment closed: A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes (clinicaltrials.gov) - Apr 2, 2024
P1, N=218, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Rydapt (midostaurin) / Novartis
Enrollment closed: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance (clinicaltrials.gov) - Apr 2, 2024
P2, N=107, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || TAS1440 / Otsuka
Enrollment closed, Combination therapy: A Study of TAS1440 With ATRA in Subjects With r/r AML (clinicaltrials.gov) - Apr 2, 2024
P1, N=80, Active, not recruiting, Sponsor: Astex Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Single-Chain Variable Fragment Affinity Tuning Can Optimize Anti-AML CAR-NK Cell Functionality (Ballroom 2) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_2389;
- SynNotch-Gated CARs Enhance Specificity, Promote Persistence, and Reduce Toxicity in AML (Exhibit Hall) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_2247;
- Gene-Edited Hematopoietic Stem Cells to Enable Next-Generation CAR-T Cell Therapy for the Treatment of AML (Exhibit Hall) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_2243;
- The Novel Autologous AML Vaccine, TriLeukeVax, Stimulates Robust Anti-Leukemic Patient T Cell Responses (Room 318-323) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1848;
- Targeting AML with Naturally Occurring CD7 Negative T Cells Expressing CD7 CAR (Room 318-323) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1843;
- Engineering Gate CAR-T for AML Using Non-Viral Delivery Methods (Exhibit Hall) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1627;
- CD33 Targeted gd T cells for Treatment of Acute Myeloid Leukemia (Exhibit Hall) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1620;
- Examining the Reciprocal Effects of Natural Killer and Acute Myeloid Leukemia Cell Interactions on Immune Checkpoint Receptor Expression (Exhibit Hall) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1615;
- Targeting AML with Multi-Antigen Specific T Cells Engineered to Express a CAR Specific for SSX2 Peptide 41-49 (Room 339-342) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1332;
- Ex Vivo and In Vivo Generation of Dual Specific CAR T Cells for Combination CAR T/Oncolytic Virus Therapy (Room 339-342) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1330;
- Developing Adoptive Cell Therapy Strategies to Leverage Myeloid Immunity Against AML (Room 339-342) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1329;
- Development of Extracellularly Linked Concatemeric Trivalent Cytokine (ELeCTriC) Chimeric Antigen Receptor (CAR) T-Cells as Dual Conditioning and Immunotherapeutic Agents (Room 339-342) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1328;
- Chimeric Cytokine Receptors Induce Antigen-Specific Activation in Natural Killer Cells Against Acute Myeloid Leukemia (Room 339-342) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1296;
- Oligonucleotide-Based AML Immunotherapy through Targeted STAT3/DNMT1 Inhibition Combined with TLR9/IRF8 Activation (Exhibit Hall) - Apr 2, 2024 - Abstract #ASGCT2024ASGCT_1004;
- | Journal: Penalized Bayesian forward continuation ratio model with application to high-dimensional data with discrete survival outcomes. (Pubmed Central) - Apr 1, 2024
We identified nine features that map to ten unique genes, five of which have been previously associated with leukemia in the literature. In conclusion, our proposed Bayesian model is flexible, allows simultaneous variable selection and uncertainty quantification, and performed well in simulation studies and application to real data.
- | Journal: Cysteine- and glycine-rich protein 1 predicts prognosis and therapy response in patients with acute myeloid leukemia. (Pubmed Central) - Apr 1, 2024
The high CSRP1 patients showed higher sensitivity to 5-fluorouracil, gemcitabine, rapamycin, cisplatin and lower sensitivity to fludarabine. CSRP1 may serve as a potential prognostic marker and a therapeutic target for AML in the future.